| Returns | 1W : 7.8% , 1M : 0.4%,1Y : 37.1% |
| Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 7.8% | 0.4% | 37.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.8% | -8.2% | 18.1% |
| DRREDDYS LABORATORIES | -0.9% | 17.2% | 80.8% |
| DIVIS LABORATORIES | -4.4% | -5.5% | 86.8% |
| CIPLA | -0.5% | 3.5% | 66.2% |
| PIRAMAL ENTERPRISES | 2.9% | -15% | -32.7% |
| LUPIN | -3.1% | 3.2% | 32% |
| AUROBINDO PHARMA | 0.4% | -7.7% | 24.6% |
| TORRENT PHARMACEUTICALS | -1.4% | -0.5% | 57.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
8.76 1.19 2.03 - |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-72% -62% -63% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2019 2018 2017 Avg_3yrs |
0.26 0.29 0.29 0.28 |
0.8 0.9 1.05 0.92 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
4.68% 42.14% 54.56% 32.44% |
12.29% 70.63% 107.93% 102.98% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
